Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study

Model scores of the 29,894 trials active now.

Model score 10% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 7% of the time (96 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2014-05-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: effectsdiabetesgreater thantermbarrier method
  Phrases that lowered it: antiretroviralhivcd4infectedviral
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 12.9% (raises risk) · Sponsor's track record
• Collaborators: 3 (lowers risk) · Design
• Phase: 1/2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Minimum age: 18 (raises risk) · Who can join
• Trials the sponsor started in the prior 2 years: 123 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 348 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 18.2% (lowers risk) · Drug's FDA history
• Design: single group (raises risk) · Design
• Primary purpose: basic science (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Disease area, infectious disease: Yes (lowers risk) · Disease area
• Disease area, neurology: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: 94.4% (raises risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART NCT03198559 · started 2017 · scored riskier than 38% of active trials terminated
• Disulfiram Interactions With HIV Medications: Clinical Implications NCT00878306 · started 2008 · scored riskier than 11% of active trials completed
• Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020) NCT04233879 · started 2020 · scored riskier than 23% of active trials completed
• D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive Adults NCT01565850 · started 2012 · scored riskier than 20% of active trials completed
• Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF NCT02121795 · started 2014 · scored riskier than 11% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.